Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-DLMP1-LMP2 DC vaccine
- Development stage
- Unknown
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intradermal
01
Overview
The Ad-ΔLMP1-LMP2 DC vaccine is an experimental autologous dendritic cell (DC) immunotherapy designed to treat Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC). The vaccine consists of a patient's own dendritic cells that have been genetically modified using a recombinant adenovirus vector to express two specific EBV antigens: a truncated version of Latent Membrane Protein 1 (ΔLMP1) and the full-length Latent Membrane Protein 2 (LMP2). By presenting these viral antigens, the vaccine aims to stimulate a T cell-mediated immune response against NPC cells that express these proteins. Clinical evaluation in Phase II studies has demonstrated safety and the induction of delayed-type hypersensitivity responses, although clinical efficacy in advanced metastatic disease remains a focus for further optimization.
- Other names
- Ad-ΔLMP1-LMP2 DC vaccineAd-DLMP1-LMP2 transduced DC vaccineAd-DLMP-1-LMP2 transduced DC vaccineAd-DLMP 1-LMP2 transduced DC vaccine
02
Targets
LMP1 (Epstein-Barr virus latent membrane protein 1)PSMB9 (Immunoproteasome subunit beta type-1i)Epstein-Barr virus latent membrane protein 1/2-specific T-cell receptor
Beyond the preview
Go deeper on Ad-DLMP1-LMP2 DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-DLMP1-LMP2 DC vaccine.